| Literature DB >> 35889428 |
Abstract
Cytokine storm is a condition in which the immune system produces an excessive number of inflammatory signals, which can result in organ failure and death. It is also known as cytokine release syndrome, CRS, or simply cytokine storm, and it has received a lot of attention recently because of the COVID-19 pandemic. It appears to be one of the reasons why some people experience life-threatening symptoms from COVID-19, a medical condition induced by SARS-CoV-2 infection. In situations where natural substances can be exploited as therapeutics to reduce cytokine storm, the drug development process has come to the rescue. In the present study, we tested the potentiality of Andrographolide, labdane diterpenoid targeting several key cytokines that are secreted as a result of cytokine storm. We used molecular docking analyses, molecular dynamics simulations, and pharmacokinetic properties to test the stability of the complexes. The compound's binding energy with some cytokines was over -6.5 Kcal/mol. Furthermore, a post-molecular dynamics (MD) study revealed that Andrographolide was extremely stable with these cytokines. The compound's pharmacokinetic measurements demonstrated excellent properties in terms of adsorption, distribution, metabolism, and excretion. Our research revealed that this compound may be effective in lowering cytokine storm and treating severe symptoms.Entities:
Keywords: andrographolide; cytokine; interleukin
Mesh:
Substances:
Year: 2022 PMID: 35889428 PMCID: PMC9319373 DOI: 10.3390/molecules27144555
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
List of selected cytokines and their classification and roles.
| Cytokine | Classification | Origin | Receptor | Aim Cell | Role |
|---|---|---|---|---|---|
| G-CSF | Pro-inflammatory | Fibroblasts, | CD114 | Stem cells in BM | Granulocyte production |
| GM-CSF | Adaptive immunity | T cells, | CD116, CDw131 | Stem cells | Growth and differentiation of monocytes, and eosinophil, granulocytes production |
| M-CSF | Adaptive immunity | Fibroblasts, | CD115 | Stem cells | Monocyte production and |
| IL-2 | Adaptive immunity | Th1 cells | CD25 | Activated T and B cells, NK cells | Proliferation of B cells, |
| IL-3 | Adaptive immunity | T cells | CD123, CDw131 | Stem cells | Hematopoietic precursor |
| IL-4 | Adaptive immunity | Th Cells | CD124 | B cell, T cell, | Proliferation of B and cytotoxic T cells, enhances MHC class II expression, stimulates IgG and IgE production |
| IL-5 | Adaptive immunity | Th2 Cells and mast cells | CDw125, 131 | Eosinophils, | B-cell proliferation and maturation, stimulates IgA and IgM production |
| IL-6 | Pro-inflammatory | Th Cells, | CD126, 130 | B-cells, plasma cells | B-cell differentiation |
| IL-8 | Pro-inflammatory | Macrophages | IL-8R | Neutrophils | Chemotaxis for neutrophils and T cells |
| IL-10 | Anti-inflammatory | T cells, B cells, macrophages | CDw210 | B cells, | Inhibits cytokine production and mononuclear cell function |
| IL-12 | Anti-inflammatory | T cells, macrophages, monocytes | CD212 | NK cells, macrophages, tumor cells | Activates NK cells, phagocyte cell activation, endotoxic shock, tumor cytotoxicity, cachexia |
| IL-13 | Anti-inflammatory | Th2 Cells, mast cells, eosinophils, basophile and nunocytes | IL13Rα1 | Act on monocyte, fibroblast and B cell growth | Regulate eosinophilic |
| IL-17 | Pro-inflammatory | Th17 cells | IL-17R | Monocytes, neutrophils | Recruit monocytes and neutrophils to the site of infection. Activation of IL-17 in turn |
| IFN-γ | Pro-inflammatory | T Cells and NK cells | CDw119 (IFNG R1) | Various | Anti-viral, macrophage activation, increases neutrophil and monocyte function, MHC-I and -II expression on cells |
| TNF-α | Pro-inflammatory | Macrophages | CD120a, b | Macrophages | Phagocyte cell activation, |
| MIP-1α | Pro-inflammatory | Macrophages and monocytes | Hematopoietic cells | Immune responses towards | |
| MIP-1β | Pro-inflammatory | Macrophages and monocytes | Hematopoietic cells | Immune responses towards | |
| IP 10 | Pro-inflammatory | Monocytes, | Antitumor activity, and |
Figure 1Crystal structure of Andrographolide.
Molecular docking results of different cytokines with Andrographolide.
| Cytokines | PDB Code | Binding Affinity (Kcal/mol) with |
|---|---|---|
| IL-2 | 4NEJ | −4.3 |
| IL-3 | 5UWC | −7.5 |
| IL-4 | 2B8U | −6.4 |
| IL-5 | 3QT2 | −6.3 |
| IL-6 | 1ALU | −6.0 |
| IL-13 | 3BPO | −6.7 |
| IFN-γ | 6E3L | −6.2 |
| IL-8 | 1IL8 | −3.8 |
| IL-10 | 1ILK | −7.1 |
| IL-12 | 1F45 | −5.3 |
| IL-17 | 6HGO | −6.2 |
| G-GSF | 3UEZ | −7.2 |
| GM-CSF | 2GMF | −6.2 |
| IP10 | 1O7Y | −4.2 |
| M-CSF | 1HMC | −6.0 |
| MiP1α | 2X6G | −1.1 |
| MiP1β | 4RAL | −6.3 |
| TNF-α | 2AZ5 | −6.0 |
Figure 2Interactions of IL-3 (A), IL-4 (B), IL-5 (C), IL-6 (D) and IL-10 (E) with Andrographolide.
Figure 3Interaction of IL-13 (A), IFN-γ (B), TNF-α (C), G-CSF (D), GM-CSF (E), and MiP1β (F) with Andrographolide.
Molecular docking results of cytokines with known inhibitors.
| Cytokines | Binding Affinity (Kcal/mol) |
|---|---|
| IL-4-Compound 52 | −5.3 |
| IL-8-Reparixin | −5.8 |
Figure 4RMSD (A1,A2), RMSF (B1,B2), Rg (C1,C2), hydrogen bond (D1,D2), and SASA (E1,E2) results of the Andrographolide–cytokine complexes after 100 ns simulation.
Important ADME properties of Andrographolide.
| Parameters | Cytisine |
|---|---|
| Num. H-bond acceptors | 5 |
| Num. H-bond donors | 3 |
| Molecular weight (g/mol) | 350.45 |
| Lipinski violation | 0 violation |
| GI absorption | High |
| BBB permeant | No |
| CYP1A2 inhibitor | No |
| CYP2C19 inhibitor | No |
| CYP2C9 inhibitor | No |
| CYP2D6 inhibitor | No |
| CYP3A4 inhibitor | No |
| Log Kp (skin permeation) (cm/s) | −6.90 |
| PAINS | 0 alert |
| Brenk | 2 alerts: isolated_alkene, michael_acceptor_1 |
| Synthetic accessibility | 5.06 |